News

Alembic Pharma gets US FDA nod for cholesterol lowering drug

The drugs are available in the strengths of 67 mg, 134 mg and 200 mg

Alembic Pharma has received approval from the US health regulator for Fenofibrate capsules, which reduces cholesterol and triglycerides in blood.

The approved product is therapeutically equivalent to the reference listed drug product Tricor Micronized Capsules of AbbVie.

In a regulatory filing, Alembic Pharma said that “it has received final approval from the US Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) Fenofibrate capsules USP in the strengths of 67 mg, 134 mg and 200 mg.”

Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipideniia.

Quoting IQVIA, Alembic Pharma said Fenofibrate capsules USP, 67 mg, 134 mg and 200 mg have an estimated market size of $17 million for 12 months ending June 2020.

 

PTI

 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close